Patient centricity has become increasingly important in clinical trials for ALS. In this webinar, host Paul Wicks and Cathy Collet discuss the challenges of patient engagement in ALS clinical trials and the potential ways to overcome them.
Genomics-based drug discovery offers great potential for the development of targeted therapies that can offer new and better treatment options for patients. By utilising genetic and biomarker information, this approach allows us to gain insights into the fundamental causes of diseases. But this growing field is not without its challenges.
Last week, our team had the privilege of attending the European Association for the Study of the Liver (EASL) conference, where groundbreaking advancements in liver research were unveiled. The conference provided an exceptional platform for experts and researchers to exchange knowledge and foster collaboration in the field of liver disease. In discussions with fellow conference-goers, our team identified several noteworthy themes emerging as key areas of interest. These included the pivotal role of genetics, particularly the PNPLA3 gene, in driving liver fibrosis in NAFLD/MASLD, the significance of AATD SERPINA 1 - PiZZ genotype pathogenicity, and the nomenclature change in NASH and MASH. Here, we will explore these developments, shedding light on the implications they hold for the future of liver disease research and patient care.
At Sano, we know that measuring and optimising data is the key to successful execution of clinical trials. That’s why we’ve put together a three-page report on key strategies to measure and optimise your data in a way that streamlines your operations. In it, we explore the significance of data collection and integration, real-time analytics, performance metrics, and predictive modelling in the world of clinical trials. Download below to learn more!
This webinar, hosted by Lindsey Wahlstrom-Edwards, Partnerships Lead for Sano Genetics, and featuring Wayne Eskridge and Dr. Neeraj Mistry from the Fatty Liver Foundation, was an informative session on the genetics and lifestyle factors that contribute to metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
This webinar, moderated by Patrick Short, CEO and co-founder of Sano Genetics, and featuring two panelists, Jessi Keavney and Krista Qualmann, discussed the importance of genetic testing in understanding an individual's risk for Parkinson's disease.
Clinical trials depend on sustained patient participation, yet recruitment shortfalls and early withdrawals remain two of the most common causes of trial delays and failure. Understanding where and why engagement breaks down is a prerequisite for addressing it effectively. By fostering a strong relationship between researchers and patients, patient engagement can help improve enrollment, boost retention rates, improve the accuracy of data collected, and ensure the trial's overall success. Understanding how engagement operates across the trial timeline and where it typically breaks down is essential for sponsors designing precision studies where participant retention and data continuity are directly tied to program outcomes.
Electronic consent, or e-consent, is a method of obtaining informed consent through an electronic system rather than a paper form. It typically incorporates multimedia components such as videos and interactive presentations to explain the risks and benefits of trial participation, supporting different learning styles and improving participant comprehension. E-consent can be conducted in the clinic or remotely, with participants accessing the platform through a website or dedicated application.
Recently, our team was honoured to attend the World Orphan Drug Congress USA in Boston. The event brought together key stakeholders, experts, and industry leaders in the field of orphan drugs and rare diseases, and provided a platform for collaboration, knowledge sharing, and innovation in the pursuit of improved treatments for rare diseases. The Sano team enjoyed the insightful keynote presentations, interactive panel discussions, and valuable networking opportunities.
Clinical trials are the foundation of modern medicine. They determine which treatments reach patients and how those treatments are understood. Yet for much of history, women were excluded from this process entirely. The male body was treated as the default, and findings from male-only studies were assumed to apply to everyone.